FDA Commissioner Outlines New Plan to Increase Biosimilars by “Balancing Innovation and Competition”
Biosimilars are crucial for improving patient access to biologic drugs at an affordable cost. Biologics are now key in the treatment of cancer and autoimmune conditions. But cost remains an obstacle to access to drug therapy.
While the industry does its part to improve the quality and completeness of applications, the FDA is taking action to enhance the efficiency of its review process.
Results 1 - 2 of 2